Medistem to Provide Update on Heart Failure Clinical Trial at Noble Life Sciences Exposition
Medistem Inc.Thomas IchimChief Executive Officer858-349-3617twitter: @thomasichim
Medistem Inc (Pink Sheets:MEDS), a clinical stage adult stem cell company, today announced that its CEO Dr. Thomas Ichim will attend and present at BIOX; Noble Financial Capital Markets’ Life Sciences Exposition to be held at the University of Connecticut, Stamford Campus on September, 24 at 9 AM.
Following the event, a high-definition video webcast of Medistem’s presentation and a copy of the presentation materials will be available on the Company's web site , or through the Noble Financial websites: , or . You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast will be archived on for 90 days following the event.
A short video describing Medistem and its new universal donor stem cell product, the Endometrial Regenerative Cell (ERC) can be found at .
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia and congestive heart failure. Currently the company is running clinical trials for these two indications.
Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in New York, Boston, New Jersey, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in January in South Florida featuring 150 presenting companies from across North America and total attendance of close to 600. For more information:
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.
Photos/Multimedia Gallery Available: